NUS researchers identify molecular switch driving TNBC treatment resistance
Researchers at the National University of Singapore have identified a protein called DP103 that drives treatment resistance in triple-negative breast cancer. Blocking this protein, potentially in combination with the drug RX-5902, significantly reduced tumor growth in laboratory models.
Why it matters
This discovery offers a potential new therapeutic pathway for treating one of the most aggressive and difficult-to-treat forms of breast cancer.
Researchers at the National University of Singapore (NUS) have identified a potential molecular ‘master switch’ that drives tumour growth and treatment resistance in triple-negative breast cancer (TNBC), one of the most aggressive forms of the disease.
The team found that blocking the regulator, known as DP103, reduced cancer cell growth and spread in laboratory models. The findings also suggest DP103 could potentially serve as a biomarker to identify patients who may benefit from treatment with the investigational drug RX-5902, also known as Supinoxin.
TNBC accounts for around 15 to 20 percent of breast cancers and is associated with a high risk of early recurrence, metastasis and poor survival. Unlike some other breast cancers, it lacks established targeted therapies against common molecular drivers.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in